• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Plasma cell disorders supress mucosal anti-bacterial immunity: another dimension of immunoparesis in plasma cell neoplasms.

作者信息

Faustini Sian, Chan Y L Tracey, Evans Lilli, Collman Emily, Rapson Alec, Backhouse Claire, Emery Annabelle, Campbell John P, Moore Sally, Richter Alex, Pratt Guy, Drayson Mark T, Heaney Jennifer L J

机构信息

Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

University Hospitals Birmingham NHS Trust, Birmingham, UK.

出版信息

Leukemia. 2024 Nov;38(11):2501-2504. doi: 10.1038/s41375-024-02398-1. Epub 2024 Sep 7.

DOI:10.1038/s41375-024-02398-1
PMID:39244631
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11519000/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba41/11519000/3822386f9a44/41375_2024_2398_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba41/11519000/3822386f9a44/41375_2024_2398_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba41/11519000/3822386f9a44/41375_2024_2398_Fig1_HTML.jpg

相似文献

1
Plasma cell disorders supress mucosal anti-bacterial immunity: another dimension of immunoparesis in plasma cell neoplasms.浆细胞疾病抑制黏膜抗菌免疫：浆细胞肿瘤免疫不全的另一个方面。
Leukemia. 2024 Nov;38(11):2501-2504. doi: 10.1038/s41375-024-02398-1. Epub 2024 Sep 7.
2
Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.新诊断多发性骨髓瘤患者的免疫麻痹：对丹麦人群总生存期和无进展生存期的影响。
PLoS One. 2017 Dec 7;12(12):e0188988. doi: 10.1371/journal.pone.0188988. eCollection 2017.
3
Clinical Considerations for Immunoparesis in Multiple Myeloma.多发性骨髓瘤免疫球蛋白缺乏症的临床考量
Cancers (Basel). 2022 May 3;14(9):2278. doi: 10.3390/cancers14092278.
4
Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation.ASCT 后 1 年免疫抑制恢复与接受自体干细胞移植的有症状多发性骨髓瘤患者的有利生存独立相关。
Ann Hematol. 2019 May;98(5):1177-1184. doi: 10.1007/s00277-018-3574-4. Epub 2019 Jan 4.
5
Soluble TIM3 and Its Ligands Galectin-9 and CEACAM1 Are in Disequilibrium During Alcohol-Related Liver Disease and Promote Impairment of Anti-bacterial Immunity.可溶性TIM3及其配体半乳糖凝集素-9和癌胚抗原相关细胞黏附分子1在酒精性肝病期间处于失衡状态，并促进抗菌免疫功能受损。
Front Physiol. 2021 Mar 10;12:632502. doi: 10.3389/fphys.2021.632502. eCollection 2021.
6
Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis.非移植多发性骨髓瘤患者在诱导或维持治疗期间发生严重且持续的免疫抑制是预后不良的标志。
Hematology. 2024 Dec;29(1):2329378. doi: 10.1080/16078454.2024.2329378. Epub 2024 Mar 12.
7
Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type.免疫球蛋白轻链淀粉样变性诊断时的免疫麻痹状态因治疗方案类型而异，会影响反应和生存。
Haematologica. 2016 Sep;101(9):1102-9. doi: 10.3324/haematol.2016.147041. Epub 2016 Jun 16.
8
Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation.诊断时出现症状的多发性骨髓瘤中的免疫麻痹会影响含硼替佐米诱导治疗的无进展生存期，但不影响自体造血干细胞移植巩固治疗。
Int J Hematol. 2019 Feb;109(2):169-174. doi: 10.1007/s12185-018-2547-7. Epub 2018 Oct 11.
9
Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients.深度和部分免疫抑制是新诊断多发性骨髓瘤患者的预后不良因素。
Leuk Lymphoma. 2021 Apr;62(4):883-890. doi: 10.1080/10428194.2020.1855345. Epub 2020 Dec 4.
10
Partial immunoparesis contributes to risk of early infections in patients with multiple myeloma.部分免疫轻瘫会增加多发性骨髓瘤患者早期感染的风险。
Transl Cancer Res. 2021 Dec;10(12):5258-5266. doi: 10.21037/tcr-21-1627.

本文引用的文献

1
Guardians of the oral and nasopharyngeal galaxy: IgA and protection against SARS-CoV-2 infection.守护口腔和鼻咽星系：IgA 与预防 SARS-CoV-2 感染
Immunol Rev. 2022 Aug;309(1):75-85. doi: 10.1111/imr.13118. Epub 2022 Jul 11.
2
Investigating the utility of saliva immunoglobulins for the detection of myeloma and using myeloma proteins to clarify partition between oral and systemic immunity.研究唾液免疫球蛋白在骨髓瘤检测中的应用，并利用骨髓瘤蛋白阐明口腔和全身免疫之间的分区。
Eur J Haematol. 2022 Jun;108(6):493-502. doi: 10.1111/ejh.13758. Epub 2022 Feb 28.
3
Salivary antibody responses to ten-valent pneumococcal conjugate vaccination following two different immunization schedules in a healthy birth cohort.
健康出生队列中两种不同免疫接种方案对 10 价肺炎球菌结合疫苗的唾液抗体反应。
Vaccine. 2022 Jan 24;40(3):408-413. doi: 10.1016/j.vaccine.2021.12.013. Epub 2021 Dec 24.
4
Invasive pneumococcal disease among adults with hematological and solid organ malignancies: A population-based cohort study.成人血液系统和实体器官恶性肿瘤患者的侵袭性肺炎球菌病：一项基于人群的队列研究。
Int J Infect Dis. 2021 May;106:237-245. doi: 10.1016/j.ijid.2021.03.072. Epub 2021 Mar 26.
5
Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management.多发性骨髓瘤患者在疾病发作时、治疗反应时和缓解期的抗细菌抗体：对患者管理的影响。
Blood Cancer J. 2020 Nov 4;10(11):114. doi: 10.1038/s41408-020-00370-7.
6
Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials.新诊断多发性骨髓瘤中免疫抑制的特征及其对新旧多发性骨髓瘤试验中无进展生存和总生存的影响。
Leukemia. 2018 Aug;32(8):1727-1738. doi: 10.1038/s41375-018-0163-4. Epub 2018 Jun 20.
7
The utility of saliva for the assessment of anti-pneumococcal antibodies: investigation of saliva as a marker of antibody status in serum.唾液用于评估抗肺炎球菌抗体的效用：唾液作为血清中抗体状态标志物的研究。
Biomarkers. 2018 Mar;23(2):115-122. doi: 10.1080/1354750X.2016.1265009. Epub 2016 Dec 12.
8
Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.冒烟型多发性骨髓瘤进展的危险因素：一项基于丹麦人群的队列研究。
Eur J Haematol. 2016 Sep;97(3):303-9. doi: 10.1111/ejh.12728. Epub 2016 Feb 5.
9
Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database.不符合接受造血干细胞支持下大剂量治疗条件的多发性骨髓瘤患者的早期死亡原因：一项基于丹麦全国骨髓瘤数据库的研究
Am J Hematol. 2015 Apr;90(4):E73-4. doi: 10.1002/ajh.23932. Epub 2015 Feb 2.
10
Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma.在有症状多发性骨髓瘤患者中，未受累免疫球蛋白的保留水平与有利结局独立相关。
Leukemia. 2014 Oct;28(10):2075-9. doi: 10.1038/leu.2014.110. Epub 2014 Mar 18.